Literature DB >> 9973246

The molecular biology of breast cancer: accelerating clinical applications.

D A Dillon1, C L Howe, S Bosari, J Costa.   

Abstract

Recent advances in basic science have led to a better understanding of the molecular events important in the pathogenesis of breast cancer. Very little of this new knowledge, however, has had a significant impact on improving the diagnosis and therapy of breast cancer. We review many of the molecular events important in the pathogenesis of breast cancer, including inherited abnormalities in BRCA-1 and BRCA-2, p53, ATM, and PTEN and sporadic alterations in growth factors and their receptors, signal transduction, cell cycle control, DNA repair, cell death, angiogenesis, and invasion and metastasis. We suggest ways to speed up clinical applications of the new molecular knowledge base through the use of preclinical disease models, development of high throughput sample analysis and infrastructure programs to facilitate translational research, implementation of practice guidelines, and development of regional oncology networks. Only through the implementation of such a deliberate, multifaceted strategy will the gap between the research laboratory and the clinic be closed.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9973246     DOI: 10.1615/critrevoncog.v9.i2.30

Source DB:  PubMed          Journal:  Crit Rev Oncog        ISSN: 0893-9675


  5 in total

Review 1.  TGF-beta signaling in mammary gland development and tumorigenesis.

Authors:  L M Wakefield; E Piek; E P Böttinger
Journal:  J Mammary Gland Biol Neoplasia       Date:  2001-01       Impact factor: 2.673

Review 2.  Cancer biomarkers: selecting the right drug for the right patient.

Authors:  Gary J Kelloff; Caroline C Sigman
Journal:  Nat Rev Drug Discov       Date:  2012-02-10       Impact factor: 84.694

3.  PTEN encoding product: a marker for tumorigenesis and progression of gastric carcinoma.

Authors:  Lin Yang; Li-Ge Kuang; Hua-Chuan Zheng; Jin-Yi Li; Dong-Ying Wu; Su-Min Zhang; Yan Xin
Journal:  World J Gastroenterol       Date:  2003-01       Impact factor: 5.742

Review 4.  Transforming growth factor-beta and breast cancer: Transforming growth factor-beta/SMAD signaling defects and cancer.

Authors:  M Kretzschmar
Journal:  Breast Cancer Res       Date:  2000-02-21       Impact factor: 6.466

5.  Dual blockade of EGFR and ERK1/2 phosphorylation potentiates growth inhibition of breast cancer cells.

Authors:  D C Lev; L S Kim; V Melnikova; M Ruiz; H N Ananthaswamy; J E Price
Journal:  Br J Cancer       Date:  2004-08-16       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.